# An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)

> **NCT05959070** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 154 (actual)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05959070
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-09
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-03-21
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959070, "An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05959070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*